|
Index of reports
> Cases with Platelet Count Decreased ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include platelet count decreased. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of Next >>
Possible Cytarabine side effects in female
Reported by a physician from United Kingdom on 2012-08-10
Patient: female
Reactions: Neutropenic Sepsis, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 40mg every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-21
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-20
Cisplatin
Dosage: 100mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-21
Cytarabine
Dosage: 4gm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-22
Possible Cytarabine side effects in female
Reported by a physician from United Kingdom on 2012-08-07
Patient: female
Reactions: Sepsis, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-20
Cisplatin
Dosage: 100mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-21
Cytarabine
Dosage: 4gm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-22
Dexamethasone
Dosage: 40mg every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-21
Possible Cytarabine side effects in 59 year old female
Reported by a physician from United States on 2012-07-18
Patient: 59 year old female
Reactions: Respiratory Failure, Platelet Count Decreased, Febrile Neutropenia, Upper Gastrointestinal Haemorrhage, Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: unk
Indication: Acute Myeloid Leukaemia
Start date: 2012-02-11
Cytarabine
Dosage: 1920 mg, cyclic
Start date: 2012-05-16
End date: 2012-05-16
Sprycel
Dosage: 600 mg, cyclic
Administration route: Oral
Start date: 2012-05-16
End date: 2012-05-26
Sprycel
Dosage: unk
Administration route: Oral
Indication: Acute Myeloid Leukaemia
Start date: 2012-02-11
Possible Cytarabine side effects in female
Reported by a physician from United Kingdom on 2012-07-16
Patient: female
Reactions: Sepsis, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-20
Cisplatin
Dosage: 100mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-21
Dexamethasone
Dosage: 40mg every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-21
Cytarabine
Dosage: 4gm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-22
Possible Cytarabine side effects in 38 year old female
Reported by a physician from United States on 2012-06-25
Patient: 38 year old female
Reactions: White Blood Cell Count Decreased, Anaemia, Febrile Neutropenia, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Methotrexate Sodium
Dosage: 1880 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Leucovorin Calcium
Dosage: 125 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Cytarabine
Dosage: 5640 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Methylprednisolone
Dosage: 300 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Sprycel
Dosage: 980 mg, unk
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Possible Cytarabine side effects in 5 year old female
Reported by a physician from United States on 2012-05-29
Patient: 5 year old female, weighing 21.4 kg (47.1 pounds)
Reactions: White Blood Cell Count Decreased, Bacterial Infection, Febrile Neutropenia, Endocarditis, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mitoxantrone
Indication: Acute Promyelocytic Leukaemia
Start date: 2011-12-19
Trisenox
Indication: Acute Promyelocytic Leukaemia
Start date: 2012-04-13
Cytarabine
Indication: Acute Promyelocytic Leukaemia
Start date: 2011-12-19
Cytarabine
Dosage: high dose
Start date: 2012-04-25
Tretinoin
Indication: Acute Promyelocytic Leukaemia
Start date: 2011-12-19
Possible Cytarabine side effects in male
Reported by a individual with unspecified qualification from United States on 2012-05-14
Patient: male, weighing 103.3 kg (227.3 pounds)
Reactions: Oral Mucosal Blistering, Anaemia, Rash Papular, Blood Blister, Headache, Haemolysis, Dysgeusia, Haemoglobin Decreased, Ecchymosis, Platelet Count Decreased, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytoxan
Dosage: 4600 mg
Cytarabine
Dosage: 2890 mg
Vincristine Sulfate
Dosage: 4 mg
PEG-L -Asparaginase (K-H)
Dosage: 5700 unit
Methotrexate
Dosage: 60 mg
Mercaptopurine
Dosage: 3900 mg
Possible Cytarabine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-05-14
Patient: female, weighing 43.8 kg (96.4 pounds)
Reactions: Disinhibition, Hypoaesthesia Oral, Protrusion Tongue, Balance Disorder, Oxygen Saturation Decreased, Grimacing, Nausea, Blepharospasm, Abnormal Behaviour, Body Temperature Decreased, Haemoglobin Decreased, Affect Lability, Heart Rate Increased, Platelet Count Decreased, Memory Impairment, Inappropriate Affect, Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Hydrocortisone
Dosage: 45 mg
End date: 2012-04-25
Daunorubicin Hydrochloride
Dosage: 140 mg
End date: 2012-03-28
Mercaptopurine
Dosage: 1150 mg
End date: 2012-04-24
Vincristine Sulfate
Dosage: 4 mg
End date: 2012-05-03
Cytarabine
Dosage: 1090 mg
End date: 2012-04-25
PEG-L-Aspraginase (Pegasparagase, Oncospar)
Dosage: 3375 iu
End date: 2012-04-25
Methotrexate
Dosage: 45 mg
End date: 2012-04-25
Cyclophosphamide
Dosage: 2800 mg
End date: 2012-05-09
Possible Cytarabine side effects in
Reported by a health professional (non-physician/pharmacist) from China on 2012-05-11
Patient:
Reactions: Hypersensitivity, Petechiae, Off Label Use, Neurotoxicity, Hepatotoxicity, Granulocytopenia, Bone Marrow Failure, White Blood Cell Count Decreased, Gastrointestinal Toxicity, Anaemia, Nephropathy Toxic, Urinary Tract Infection, Toxicity To Various Agents, Soft Tissue Infection, Sepsis, Platelet Count Decreased, Infection
Drug(s) suspected as cause:
Mesna
Indication: Acute Myeloid Leukaemia
Epirubicin
Indication: non-Hodgkin's Lymphoma
Epirubicin
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: non-Hodgkin's Lymphoma
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Vindesine
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Vindesine
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: non-Hodgkin's Lymphoma
Mesna
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Leucovorin Calcium
Possible Cytarabine side effects in 18 year old male
Reported by a physician from United States on 2012-05-10
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Pegaspargase
Dosage: 2500 iu, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-25
End date: 2012-03-02
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Vincristine
Dosage: 2 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 50 mg, bid
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Cytarabine
Dosage: 70 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Possible Cytarabine side effects in 71 year old male
Reported by a physician from Japan on 2012-05-10
Patient: 71 year old male
Reactions: White Blood Cell Count Decreased, Interstitial Lung Disease, Anaemia, Platelet Count Decreased, Pleural Effusion
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Sprycel
Dosage: 70 mg, 2x/day
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-22
Neupogen
Indication: Acute Lymphocytic Leukaemia
Oncovin
Indication: Acute Lymphocytic Leukaemia
Idarubicin HCL
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-08
End date: 2012-02-15
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-08
End date: 2012-02-15
Other drugs received by patient: Candesartan Cilexetil; Dexamethasone Sodium Phosphate; Fluconazole; Allopurinol; Polymyxin B Sulfate; Cotrim; Neutrogin
Possible Cytarabine side effects in
Reported by a health professional (non-physician/pharmacist) from China on 2012-05-10
Patient:
Reactions: Hypersensitivity, Neurotoxicity, Off Label Use, Hepatotoxicity, Granulocytopenia, Bone Marrow Failure, White Blood Cell Count Decreased, Gastrointestinal Toxicity, Nephropathy Toxic, Urinary Tract Infection, Anaemia, Soft Tissue Infection, Acute Lymphocytic Leukaemia, Sepsis, Platelet Count Decreased, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Mesna
Indication: Acute Myeloid Leukaemia
Methotrexate
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Mesna
Indication: non-Hodgkin's Lymphoma
Vindesine
Indication: Acute Lymphocytic Leukaemia
Vindesine
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Dexamethasone TAB
Indication: non-Hodgkin's Lymphoma
Dexamethasone TAB
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Leucovorin Calcium
Possible Cytarabine side effects in male
Reported by a individual with unspecified qualification from United States on 2012-04-26
Patient: male, weighing 89.8 kg (197.6 pounds)
Reactions: White Blood Cell Count Decreased, Platelet Count Decreased, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Possible Cytarabine side effects in male
Reported by a physician from United States on 2012-04-17
Patient: male, weighing 91.7 kg (201.7 pounds)
Reactions: Pneumonia, Dyspnoea, Vocal Cord Paresis, Hypotension, Pulmonary Alveolar Haemorrhage, Scab, Laryngeal Oedema, Febrile Infection, Herpes Simplex, Platelet Count Decreased, Hypoxia, Tachypnoea
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 1470 mg
End date: 2012-03-26
Daunorubicin HCL
Dosage: 375 mg
End date: 2012-03-22
Possible Cytarabine side effects in 18 year old male
Reported by a consumer/non-health professional from United States on 2012-04-13
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: 2 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 50 mg, bid
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Pegaspargase
Dosage: 2500 iu, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-25
End date: 2012-03-02
Cytarabine
Dosage: 70 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Possible Cytarabine side effects in male
Reported by a individual with unspecified qualification from United States on 2012-04-13
Patient: male, weighing 91.7 kg (201.7 pounds)
Reactions: Dyspnoea, Vocal Cord Paresis, Hypotension, Pulmonary Alveolar Haemorrhage, Pyrexia, Laryngeal Oedema, Herpes Simplex, Platelet Count Decreased, Hypoxia, Tachypnoea
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 1470 mg
End date: 2012-03-26
Daunorubicin HCL
Dosage: 375 mg
End date: 2012-03-22
Possible Cytarabine side effects in 65 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-05
Patient: 65 year old male, weighing 125.5 kg (276.1 pounds)
Reactions: White Blood Cell Count Decreased, Pulmonary Oedema, Platelet Count Decreased, Device Related Infection, Neutrophil Count Decreased, Rash Maculo-Papular, Cerebrovascular Accident, Pneumonitis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Idarubicin HCL
Dosage: 12 milligram/sq. meter
Start date: 2011-12-05
End date: 2011-12-23
Cytarabine
Dosage: 100 milligram/sq. meter
Start date: 2012-02-17
End date: 2012-02-25
Idarubicin HCL
Dosage: 12 milligram/sq. meter
Start date: 2012-02-17
End date: 2012-02-22
Revlimid
Dosage: 30 milligram
Administration route: Oral
Start date: 2012-02-17
End date: 2012-02-24
Revlimid
Dosage: 30 milligram
Administration route: Oral
Start date: 2011-12-05
End date: 2011-12-23
Cytarabine
Dosage: 100 milligram/sq. meter
Start date: 2011-12-05
End date: 2011-12-23
Other drugs received by patient: Neupogen
Possible Cytarabine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-04-05
Patient: female, weighing 53.6 kg (117.9 pounds)
Reactions: Abdominal Pain, Tachycardia, Faeces Discoloured, Haematemesis, Posterior Reversible Encephalopathy Syndrome, Enterocolitis, Nausea, Hepatic Steatosis, Convulsion, Cholelithiasis, Mallory-Weiss Syndrome, Bacteraemia, Platelet Count Decreased, Ammonia Increased, Neutropenia, Hypertension, Septic Shock
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mercaptopurine
Dosage: 2500 mg
Cyclophosphamide
Dosage: 2900 mg
Cytarabine
Dosage: 216 mg
Possible Cytarabine side effects in 18 year old male
Reported by a physician from United States on 2012-04-03
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: White Blood Cell Count Decreased, Abdominal Pain, Metabolic Acidosis, Clostridium Test Positive, Urine Output Decreased, Hypotension, Hyponatraemia, Capillary Leak Syndrome, Platelet Count Decreased, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Oncaspar
Dosage: 2500 iu;x1;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Doxorubicin HCL
Dosage: 60 mg/m**2;x1;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Velcade
Dosage: 1.3 mg/m**2; qd; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Vincristine
Dosage: 1.5 mg/m**2;qd;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 20 mg/m**2;qd;po
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Cytarabine
Dosage: 70 mg;x1;inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: inth
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in female
Reported by a physician from United States on 2012-03-28
Patient: female, weighing 84.3 kg (185.5 pounds)
Reactions: Hyperglycaemia, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Daunorubicin HCL
Dosage: 96 mg
Methylprednisolone
Dosage: 1320 mg
Vincristine Sulfate
Dosage: 2 mg
Cytarabine
Dosage: 70 mg
Methotrexate
Dosage: 15 mg
PEG-L-Asparaginase (K-H)
Dosage: 48000 unit
Other drugs received by patient: Acetaminophen; Protonix; Alteplase; Bactrim; Docusate Sodium; Magnesium Sulfate; Zofran; Acyclovir; Morphine; Insulin / Lispro; Lorazepam; Odanesetron; Scopalamine; Biotene Mouth Rinse; Lantus; Lomotil; Allopurinol; Cefazolin; Diphenhydramine HCL; Micafungin; Ceftazidime; Vicodin; Zolpidem; Clotrimazole; Dextrose; Insulin / Glargine; Medroxyprogesterone; Nystatin; Potassium Chloride; Sodium Chloride
Possible Cytarabine side effects in 18 year old male
Reported by a consumer/non-health professional from United States on 2012-03-13
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Cytarabine
Dosage: 70 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
Pegaspargase
Dosage: 2500 iu, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Prednisone TAB
Dosage: 20 mg/m2, cyclic
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Possible Cytarabine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-03-13
Patient: female, weighing 53.6 kg (117.9 pounds)
Reactions: Dyspnoea, Tachycardia, Mental Status Changes, Hepatic Steatosis, Cholelithiasis, Mallory-Weiss Syndrome, Bacteraemia, Sepsis, Ammonia Increased, Platelet Count Decreased, Enterocolitis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: 30 mg
PEG-L Asparaginase (K-H)
Dosage: 3625 k
Mercaptopurine
Dosage: 2500 mg
Cytarabine
Dosage: 216 mg
Cyclophosphamide
Dosage: 2900 mg
Vincristine Sulfate
Dosage: 4 mg
Possible Cytarabine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-02-24
Patient: female, weighing 88.0 kg (193.6 pounds)
Reactions: Agitation, Blood Bilirubin Increased, Confusional State, Haemorrhage, Body Temperature Increased, Acidosis, Multi-Organ Failure, Haematocrit Decreased, Oxygen Saturation Decreased, Dyspnoea, Alanine Aminotransferase Increased, General Physical Health Deterioration, Haemoglobin Decreased, Aspartate Aminotransferase Increased, Platelet Count Decreased, Pulse Absent, Septic Shock, Staphylococcus Test Positive
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Daunorubicin HCL
Dosage: 360 mg
End date: 2012-02-10
Cytarabine
Dosage: 1400 mg
End date: 2012-02-04
Possible Cytarabine side effects in male
Reported by a physician from United States on 2012-02-23
Patient: male, weighing 21.5 kg (47.3 pounds)
Reactions: Bacillus Test Positive, Platelet Count Decreased, Headache, Pyrexia, Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 5400 mg
End date: 2012-02-05
Mitoxantrone Hydrochloride
Dosage: 18 mg
End date: 2012-02-06
Tretinoin
Dosage: 280 mg
End date: 2012-02-16
Possible Cytarabine side effects in 18 year old male
Reported by a physician from United States on 2012-02-21
Patient: 18 year old male, weighing 72.0 kg (158.4 pounds)
Reactions: Respiratory Failure, Platelet Count Decreased, Herpes Zoster, Klebsiella Sepsis
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: ;x1; inth ;x1; inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2011-12-29
Methotrexate
Dosage: ;x1; inth ;x1; inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-01-13
End date: 2012-01-13
Prednisone TAB
Dosage: 20 ug/ m**2; bid; po
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
Vincristine
Dosage: 1.5 mg/ m**2; qw; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2012-01-28
Velcade
Dosage: 1.3 mg/m**2; qd; iv
Indication: Acute Leukaemia
Start date: 2011-12-29
End date: 2011-12-30
Cytarabine
Dosage: ;x1; inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2011-12-29
Oncaspar
Dosage: 2500 iu/m2; qw; im
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2012-01-28
Doxorubicin HCL
Dosage: 60 mg/ m**2; qd; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2011-12-30
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
Possible Cytarabine side effects in male
Reported by a physician from United States on 2012-02-08
Patient: male, weighing 103.9 kg (228.6 pounds)
Reactions: Thrombosis, Pain, Chills, Pyrexia, Erythema, Feeling Hot, Blindness Unilateral, Mass, Muscular Weakness, Staphylococcal Sepsis, Retinitis, Choroidal Effusion, Platelet Count Decreased, Abscess, Neutropenia, Choroidal Detachment
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Daunorubicin HCL
End date: 2011-10-27
Cytarabine
Dosage: 41220 mg
End date: 2011-12-22
Possible Cytarabine side effects in male
Reported by a individual with unspecified qualification from United States on 2012-02-07
Patient: male, weighing 103.9 kg (228.6 pounds)
Reactions: Vitritis, Leukaemic Infiltration, Retinal Detachment, Chills, Pyrexia, Catheter Site Discharge, Myalgia, Malaise, Device Deployment Issue, Blindness Unilateral, Eye Abscess, Muscle Spasms, Renal Failure Acute, Exophthalmos, Cellulitis, Visual Field Defect, Mass, Staphylococcal Sepsis, Eye Pain, Choroidal Effusion, Joint Abscess, Conjunctival Haemorrhage, Arthritis Infective, Ocular Hyperaemia, Retinal Exudates, Purulence, Platelet Count Decreased, Neutropenia, Asthenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 41220 mg
End date: 2011-12-22
Daunorubicin HCL
End date: 2011-10-27
Possible Cytarabine side effects in 9 year old female
Reported by a physician from United States on 2012-01-30
Patient: 9 year old female, weighing 39.4 kg (86.7 pounds)
Reactions: Tachycardia, Pulmonary Embolism, Pyrexia, Constipation, Somnolence, Hypokalaemia, Partial Seizures, Sinusitis, Blepharospasm, Atrial Thrombosis, Hypotension, Cerebral Atrophy, Rash, Varicella Virus Test Positive, Tremor, Haemoglobin Decreased, Fungal Infection, Bacteraemia, Lacunar Infarction, Hypoalbuminaemia, Platelet Count Decreased, Neutropenia, Seizure Like Phenomena
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 100 mg, 3x/day, subuctaneous; 100 mg once, subcutaneous
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-07
End date: 2011-06-10
Cytarabine
Dosage: 100 mg, 3x/day, subuctaneous; 100 mg once, subcutaneous
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-13
End date: 2011-06-16
Vincristine Sulfate
Dosage: 2 mg, weekly, intravenous; 1.9 mg, single, intravenous
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-04-08
End date: 2011-04-29
Vincristine Sulfate
Dosage: 2 mg, weekly, intravenous; 1.9 mg, single, intravenous
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-20
End date: 2011-06-20
*peg-Asparaginase (Asparaginase) Unknown
Dosage: 3150 iu, single, intramuscular
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-20
End date: 2011-06-20
Methotrexate
Dosage: see image
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-06
End date: 2011-06-06
Methotrexate
Dosage: see image
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-13
End date: 2011-06-13
Methotrexate
Dosage: see image
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-05-06
End date: 2011-05-06
Methotrexate
Dosage: see image
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-20
End date: 2011-06-20
Methotrexate
Dosage: see image
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-04-15
End date: 2011-04-15
Dalteparin Sodium
Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
Indication: Pulmonary Embolism
Start date: 2011-05-13
End date: 2011-06-26
Dalteparin Sodium
Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
Indication: Atrial Thrombosis
Start date: 2011-05-13
End date: 2011-06-26
Dalteparin Sodium
Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
Indication: Pulmonary Embolism
Start date: 2011-06-27
Dalteparin Sodium
Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
Indication: Atrial Thrombosis
Start date: 2011-06-27
Cyclophosphamide
Dosage: 1300 mg single, intravenous; 100mg once, subcutaneous
Start date: 2011-06-06
End date: 2011-06-06
Mercaptopurine
Dosage: 75 mg, once daily six days per week, oral; 100 mg, once per day on seventh day of week, oral
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-06
End date: 2011-06-19
Mercaptopurine
Dosage: 75 mg, once daily six days per week, oral; 100 mg, once per day on seventh day of week, oral
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-06-06
End date: 2011-06-19
Other drugs received by patient: Zofran; Bactrim; Sodium Chloride 0.9%; Heparin; Ranitidine Hydrochloride; Emla; Acetaminophen
Possible Cytarabine side effects in
Reported by a individual with unspecified qualification from Germany on 2012-01-26
Patient:
Reactions: White Blood Cell Count Decreased, Pneumonia, Hyperbilirubinaemia, Dyspnoea, Febrile Neutropenia, Pancytopenia, Toxicity To Various Agents, Stem Cell Transplant, Mucosal Inflammation, Interstitial Lung Disease, Platelet Count Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Etoposide
Dosage: days 4-7
Indication: B-Cell Lymphoma
Mabthera
Dosage: days 1 and 8
Indication: B-Cell Lymphoma
Cytarabine
Dosage: days 4-7
Indication: B-Cell Lymphoma
Dexamethasone
Dosage: days 1-10
Administration route: Oral
Indication: B-Cell Lymphoma
Melphalan Hydrochloride
Dosage: day 3
Indication: B-Cell Lymphoma
Carmustine
Dosage: day 2
Indication: B-Cell Lymphoma
Possible Cytarabine side effects in female
Reported by a physician from United States on 2011-11-17
Patient: female, weighing 67.6 kg (148.7 pounds)
Reactions: Abdominal Pain, Disseminated Intravascular Coagulation, Hepatic Failure, Gastrointestinal Necrosis, Caecitis, Haemodynamic Instability, Vaginal Haemorrhage, Adhesion, Haematoma, Renal Failure Acute, Neutropenic Colitis, Vomiting, General Physical Health Deterioration, Lung Disorder, Pericarditis, Sepsis, Gastrointestinal Disorder, Platelet Count Decreased, Multi-Organ Disorder
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 3680 mg
End date: 2011-10-27
Daunorubicin HCL
Dosage: 255 mg
End date: 2011-10-18
Etoposide
Dosage: 850 mg
End date: 2011-10-18
Page 1 Next >>
|
